Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1052837/000110465905053933/a05-18032_110q.htm
Exhibit 99.1
|
|
|
|
FOR IMMEDIATE RELEASE
|
Contact: |
Greg Mann |
|
|
Director |
|
|
Corporate Communications & Investor Relations |
|
|
(510) 284-6566 |
Abgenix Announces Third Quarter 2005 Financial Results
FREMONT, Calif. - October 25, 2005 - Abgenix, Inc. (NASDAQ: ABGX) today announced financial results for the third quarter ended September 30, 2005. The company reported a net loss of $36.8 million, or $0.41 per share, for the third quarter of 2005, compared to $42.4 million, or $0.48 per share, for the same period in 2004.
Net cash used in operating activities in the third quarter of 2005 was $21.8 million, compared to $36.5 million in the third quarter of 2004. During the quarter, the company repurchased approximately $13.8 million of its outstanding convertible notes due in 2007, and ended the third quarter of 2005 with $343.6 million in cash, cash equivalents and marketable securities.
“We continue to execute on our goals for 2005, including progress with our partner, Amgen, towards the initiation of our regulatory filing to the FDA for panitumumab before year-end 2005,” said Bill Ringo, president and chief executive officer of Abgenix. “Our third quarter performance reflects expense reductions realized from our recently announced restructuring and facility consolidation, efforts to expand our product portfolio, and investment in the development and potential commercialization of panitumumab.”
Revenues for the third quarter of 2005 were $4.7 million compared to $3.1 million for the same period in 2004. Revenues for the third quarter of 2005 consisted primarily of contract revenues from technology licensing agreements and included licensing revenues and an IND-related milestone from our partner Agensys. For the third quarter of 2004, revenues included a milestone payment from Amgen for advancement of denosumab (AMG-162), a XenoMouse®-derived antibody, into pivotal clinical trials for bone loss. The company’s contract revenues generally vary from period to period based on the progress of research and development efforts by the company’s collaborators and licensees.
-more-
The following information was filed by Abgenix Inc on Tuesday, October 25, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Abgenix Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abgenix Inc.
1052837 Quarterly Reports
-
10-Q Quarterly Report November 2005
- 10-Q Quarterly Report August 2005
- 10-Q Quarterly Report May 2005
- 10-Q Quarterly Report November 2004
- 10-Q Quarterly Report August 2004
